Searching across hundreds of databases

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Cysteinyl-leukotriene receptor antagonist montelukast decreases blood-brain barrier permeability but does not prevent oedema formation in traumatic brain injury.

N Biber | HZ Toklu | S Solakoglu | M Gultomruk | T Hakan | Z Berkman | FG Dulger
Brain injury | 2009 Jun

Traumatic brain injury is highly associated with the over-production of reactive oxygen species. The aim of this study was to investigate the putative neuroprotective effect of montelukast, a cysteinyl-leukotriene receptor antagonist, in a rat model of traumatic brain injury (TBI).

Pubmed ID: 19484631

TBI Model

  • Weight-drop model
  • Animal Information

  • Species: rat
  • Strain: Sprague-Dawley
  • Age (weeks): No age reported
  • Weight (grams): No weight reported
  • Assessments

    Bederson’s modified neurological test, Brain water content, Chemiluminescence (CL) assay, EB assay, MPO activity, Na/K-ATPase, Protein assay, GSH assay, ELISA

    TBI model parameters

  • Impact Depth (mm): No information available
  • Impact Duration (ms): No information available
  • Impact Velocity (m/s): No information available
  • Impactor Tip: No information available
  • Device Name

    No information available

    Associated Datasets

    No information available

    Associated Protocols

    No information available